Dongxia Zhang1, Yun Wang2, Songben Yu3, Hua Niu4, Xingji Gong1, Xia Miao5. 1. Department of Cardiothoracic Medicine, Yuhuangding Hospital Yantai, Shandong, China. 2. Department of Cardiothoracic Surgery, People's Hospital of Zhangqiu Zhangqiu, Jinan, China. 3. Department of Pharmacy, People's Hospital of Zhangqiu Zhangqiu, Jinan, China. 4. Department of Radiology, People's Hospital of Zhangqiu Zhangqiu, Jinan, China. 5. Department of Clinical Lab, People's Hospital of Weifang Weifang, China.
Abstract
UNLABELLED: Background- AIMS: Little is known about the prognostic significance of elevated serum relaxin in acute myocardial infarction (AMI) patients. The present study is designed to investigate the potential association between serum relaxin levels and the risk of AMI. MATERIALS AND METHODS: We measured circulating relaxin levels in 80 patients (median age 62.3 years) who presented with first-time AMI 8 hours after the incident. The circulating relaxin-2 levels in 80 healthy volunteers (median age 61.5 years) was also measured. Relaxin-2 was detected using enzyme immunoassay in both groups. RESULTS: Serum relaxin levels were significantly higher in patients with AMI (27.4 ± 6.3 ng/ml) compared to controls (9.2 ± 2.3 ng/ml) (P < 0.01). We found that a relaxin level > 13.8 ng/ml had a sensitivity of 79% and a specificity of 86% for predicting AMI. Relaxin revealed the higher sensitivity and specificity for diagnosing AMI. CONCLUSIONS: Elevated relaxin in plasma may be a novel biomarker for early detection of AMI.
UNLABELLED: Background- AIMS: Little is known about the prognostic significance of elevated serum relaxin in acute myocardial infarction (AMI) patients. The present study is designed to investigate the potential association between serum relaxin levels and the risk of AMI. MATERIALS AND METHODS: We measured circulating relaxin levels in 80 patients (median age 62.3 years) who presented with first-time AMI 8 hours after the incident. The circulating relaxin-2 levels in 80 healthy volunteers (median age 61.5 years) was also measured. Relaxin-2 was detected using enzyme immunoassay in both groups. RESULTS: Serum relaxin levels were significantly higher in patients with AMI (27.4 ± 6.3 ng/ml) compared to controls (9.2 ± 2.3 ng/ml) (P < 0.01). We found that a relaxin level > 13.8 ng/ml had a sensitivity of 79% and a specificity of 86% for predicting AMI. Relaxin revealed the higher sensitivity and specificity for diagnosing AMI. CONCLUSIONS: Elevated relaxin in plasma may be a novel biomarker for early detection of AMI.
Authors: Roy C K Kong; Patrick J Shilling; Derek K Lobb; Paul R Gooley; Ross A D Bathgate Journal: Mol Cell Endocrinol Date: 2010-02-06 Impact factor: 4.102
Authors: Jennifer Moriatis Wolf; Allison E Williams; Steven Delaronde; Robin Leger; Kari B Clifton; Karen B King Journal: J Hand Surg Am Date: 2013-03-06 Impact factor: 2.230
Authors: Alana Aragón-Herrera; Sandra Feijóo-Bandín; Laura Anido-Varela; Sandra Moraña-Fernández; Esther Roselló-Lletí; Manuel Portolés; Estefanía Tarazón; Oreste Gualillo; José Ramón González-Juanatey; Francisca Lago Journal: J Pers Med Date: 2022-06-21